SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-22-000104
Filing Date
2022-05-24
Accepted
2022-05-24 17:24:07
Documents
12
Period of Report
2022-05-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20220520.htm   iXBRL 8-K 38158
  Complete submission text file 0001725160-22-000104.txt   178249

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20220520.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20220520_lab.xml EX-101.LAB 24993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20220520_pre.xml EX-101.PRE 13190
6 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20220520_htm.xml XML 11265
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 22958170
SIC: 2834 Pharmaceutical Preparations